Agilis Biotherapeutics, Inc.

Agilis Biotherapeutics, Inc. specializes in developing innovative biotherapeutic solutions for patients with rare neurological diseases, focusing on gene therapy to address unmet medical needs. Founded in 2013 and headquartered in Lynnfield, US, Agilis Biotherapeutics, Inc. is dedicated to advancing gene therapy solutions.

The company was acquired by PTC Therapeutics, Inc. in July 2018 for USD 200 mn, consisting of USD 50 mn in cash and approximately USD 150 mn in stock, with potential milestone payments of USD 595 mn. Agilis Biotherapeutics, Inc. focuses on gene therapy products designed for the treatment of rare neurological disorders.

Their offerings include advanced therapeutic solutions aimed at addressing significant unmet needs in patient care, with applications developed to optimize therapeutic efficacy. The products cater to a range of healthcare providers and institutions, serving patients in North America, Europe, and Asia. The company operates under a model that generates revenue from licensing its proprietary gene therapy products to pharmaceutical partners. Recent funding rounds have strengthened their financial position, supporting continued research and development efforts.

Agilis Biotherapeutics, Inc. plans to leverage its recent acquisition by PTC Therapeutics, Inc. to expand its product pipeline and enter new markets by 2024, focusing on Europe and Asia. The funding from the acquisition will support the development of new therapies aimed at neurological disorders and strengthen partnerships with healthcare providers to enhance distribution capabilities.